Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.48 |
| ▸ | MDM4 | O15151 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.42 |
| ▸ | CASP1 | P29466 | 2/20 | 0.41 |
| ▸ | TLR2 | O60603 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17633384 | 0.85 | SLC17A5 (0.49) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL8139788 | 0.84 | CASP1 (0.48) | SLC17A5MDM4TP53CASP3CASP1 | |
| SCHEMBL6989365 | 0.84 | CASP1 (0.48) | SLC17A5MDM4TP53CASP3CASP1 | |
| SCHEMBL28259215 | 0.82 | MDM4 (0.50) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL28259217 | 0.82 | MDM4 (0.50) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL24264727 | 0.81 | SLC17A5 (0.47) | SLC17A5MDM4TP53CASP3CASP1 | |
| SCHEMBL29386847 | 0.81 | SLC17A5 (0.44) | SLC17A5MDM4TP53CASP3CASP1 | |
| SCHEMBL29624261 | 0.81 | SLC17A5 (0.49) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL19888241 | 0.80 | SLC17A5 (0.58) | SLC17A5MDM4TP53CASP3MDM2 | |
| SCHEMBL17633370 | 0.80 | MDM2 (0.51) | MDM4TP53CASP3MDM2CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-7521529-B2 | Differentially protected orthogonal lanthionine technology | ORAGENICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037963-A1 | Lantibiotics; biosynthesis; solid phase synthesis; deblocking, deprotecting | ORAGENICS, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | VIP, LGMN, LNPEP | SLC17A5 1006/4885MDM4 3168/4885TP53 4167/4885 |
| US-20070037963-A1 | Lantibiotics; biosynthesis; solid phase synthesis; deblocking, deprotecting | VIP, NISCH, COASY | SLC17A5 2377/4885MDM4 3177/4885TP53 4328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.